Skip to main content

Advertisement

SpringerLink
Log in

The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors)

  • Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

The present study investigates the effects of serum CA-125 level and CA-125 tissue positivity on first-year recurrences in patients with stage III/IV epithelial ovarian tumors.

Methods

Of the 101 patients with EOC who had undergone systematic pelvic/para-aortic lymphadenectomy between January 2003 and December 2007 recurrence did not develop in patients with stage I/II EOC. Fifty-five patients with FIGO stage III/IV EOC were evaluated in terms of serum CA-125 level and CA-125 tissue positivity. Preoperative CA-125 levels, under 35 IU/l were considered normal. To determine the expression of CA-125 immunohistochemically, stainings exceeding 10% were considered as positive.

Results

The relationship between CA-125 values and recurrence was significant in stage III/IV patients (p = 0.041/p = 0.006). The relationship between CA-125 values and recurrence was significant in the patients with serous tumor, endometrioid tumor, clear cell tumor, and undifferentiated tumor (p = 0.034/p = 0.044/p = 0.039/p = 0.043 respectively, p < 0.05). It was insignificant in mucinous tumor (p = 0.667). The relationship between CA-125 tissue expression positivity and recurrence development was significant in stage III/IV patients (p = 0.041/p = 0.029). It was significantly correlated with recurrence in the patients with serous tumor, endometrioid tumor, clear cell tumor, mucinous tumor, and undifferentiated tumor (p = 0.034/p = 0.044/p = 0.047/p = 0.036/p = 0.043 respectively, p < 0.05).

Conclusion

We were able to show that serum CA-125 values and CA-125 tissue expression can be used as markers to predict the risk of early recurrence. Many factors play an important role in the prediction of early recurrences in advanced stage EOC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kurman R (2002) Embryology of the female genital tract. In: Kurman R (ed) Blaustein’s pathology of the female genital tract, 5th edn. New York, pp 3–31

  2. Russel P (1987) Common epithelial tumours of the ovary. In: Fox H (ed) Haines and Taylor obstetrical and gynaecological pathology, vol. I, 3rd edn. Churchill Livingstone, Edinburgh, London, Melbourne and New York, pp 542–620

  3. Clement PB (2002) Anatomy and histology of the ovary. In: Kurman R (ed) Blaustein’s pathology of the female genital tract, 5th edn. New York, pp 649–650

  4. Ghaemmaghami F, Karimi Zarchi M, Hamedi B (2007) High levels of CA125 (over 1, 000 IU/ml) in patients with gynecologic disease and no malignant conditions: three cases and literature review. Arch Gynecol Obstet 276:559–561

    Article  PubMed  Google Scholar 

  5. Harlan LC, Clegg LX, Trimble EL (2003) Trends in surgery and chemotherapy for women diagnosed with ovarian Cancer in the United States. J Clin Oncol 21:3488–3494

    Article  PubMed  Google Scholar 

  6. Lenhard SM, Bufe A, Kümper C, Stieber P, Mayr D, Hertlein L et al (2009) Relapse and survival in early-stage ovarian cancer. Arch Gynecol Obstet 280:71–77

    Article  PubMed  Google Scholar 

  7. Boring CC, Squires TS, Tong T (1991) Cancer statistics. Cancer J Clin 41:19–36

    Article  CAS  Google Scholar 

  8. Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Randimbison L (1993) Epidemiologic pathology of ovarian Cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol 4:289–294

    PubMed  CAS  Google Scholar 

  9. Katsube Y, Berg JW, Silverberg SG (1982) Epidemiologic pathology of ovarian tumors: a histopathologic review of primary ovarian neoplasms diagnosed in the Denver Standard Metropolitan Statistical Area, 1 July-31 December 1969 and 1 July-31 December 1979. Int J Gynecol Pathol 1:3–16

    Article  PubMed  CAS  Google Scholar 

  10. Chiaffarino F, Parazzini F, Bosetti C, Franceschi S, Talamini R, CAnzonieri V et al (2007) Risk factors for ovarian cancer histotypes. Eur J Cancer 43:1208–1213

    Article  PubMed  Google Scholar 

  11. Chan JK, Teoh D, Hu JM, Shin JY, Osann K, Kapp DS (2008) Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:370–376

    Article  PubMed  Google Scholar 

  12. Pereira A, Magrina JF, Rey V, Cortes M, Magtibay PM (2007) Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 105:604–608

    Article  PubMed  Google Scholar 

  13. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H et al (1983) A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309:883–887

    Article  PubMed  Google Scholar 

  14. Saygili U, Guclu S, Uslu T, Erten O, Demir N, Onvural A (2002) Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 86:57–61

    Article  PubMed  Google Scholar 

  15. Tsumura N, Sakuragi N, Hareyama H, Satoh C, Oikawa M, Yamada H et al (1998) Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer 23:526–530

    Article  Google Scholar 

  16. Ayhan A, Gultekin M, Dursun P, Dogan NU, Aksan G, Guven S et al (2008) Metastatic lymph node number in epithelial ovarian carcinoma: does it have any clinical significance? Gynecol Oncol 108:428–432

    Article  PubMed  Google Scholar 

  17. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA et al (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10:3291–3300

    Article  PubMed  CAS  Google Scholar 

  18. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP et al (2005) Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99:267–277

    Article  PubMed  CAS  Google Scholar 

  19. Breitenecker G, Neunteufel W, Bieglmayer C, Kolbl H, Schieder K (1989) Comparison between tissue and serum content of CA 125, CA 19-9, and Carcinoembryonic antigen in ovarian tumors. Int J Gynecol Pathol 8:97–102

    Article  PubMed  CAS  Google Scholar 

  20. Malkasian GD, Melton LJ, O’Brien PC, Greene MH (1984) Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. Am J Obstet Gynecol 149:274–284

    PubMed  Google Scholar 

  21. Cuesta R, Maestro ML, Solana J, Vidart JA, Escudero M, Iglesias E et al (1999) Tissue quantification of CA 125 in epithelial ovarian cancer. Int J Biol Markers 14:106–114

    PubMed  Google Scholar 

  22. Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S et al (2007) CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish “MALOVA” Ovarian Cancer Study. Gynecol Oncol 104:508–515

    Article  PubMed  Google Scholar 

  23. Diamandis EP, Borgono CA, Scorilas A, Harbeck N, Dorn J, Schmitt M (2004) Human kallikrein 11: an indicator of favorable prognosis in ovarian cancer patients. Clin Biochem 37:823–829

    Article  PubMed  CAS  Google Scholar 

  24. Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM et al (2006) Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Mod Pathol 19:1386–1394

    Article  PubMed  CAS  Google Scholar 

  25. Karaferic A, Jovanovic D, Jelic S (2009) Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary. J BUON 14:635–639

    PubMed  CAS  Google Scholar 

  26. Osman N, O’Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K et al (2008) Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Ir Med J 101:245–247

    PubMed  CAS  Google Scholar 

  27. Rossi AC, Di Vagno G, Cormio G, Cazzolla A, Stefanelli S, D’Elia E et al (2004) A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer. Arch Gynecol Obstet 269:263–265

    Article  PubMed  Google Scholar 

  28. Chi DS, Zivanovic O, Palayekar MJ, Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al (2009) A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 112:6–10

    Article  PubMed  CAS  Google Scholar 

  29. Arits AH, Stoot JE, Botterweck AA, Roumen FJ, Voogd AC (2008) Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer. Int J Gynecol Cancer 18:621–628

    Article  PubMed  CAS  Google Scholar 

  30. Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM et al (2009) The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study. Cancer 115:1028–1035

    Article  PubMed  Google Scholar 

  31. Kaern J, Aghmesheh M, Nesland JM, Danielsen HE, Sandstad B, Friedlander M et al (2005) Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 15:1014–1022

    Article  PubMed  CAS  Google Scholar 

  32. Barlow TS, Przybylski M, Schilder JM, Moore DH, Look KY (2006) The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Int J Gynecol Cancer 16:496–500

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. 2nd Obstetrics and Gynecology Clinic of Izmir, Ataturk Education and Research Hospital, Izmir, Turkey

    Fatih Gundogdu, Ferit Soylu, Levent Erkan, Orkan Tatli & Sadiye Mavi

  2. Department of Obstetrics and Gynecology, Gynecology and Obstetric Clinic, Hakkari State Hospital, 30000, Hakkari, Turkey

    Ali Yavuzcan

Authors
  1. Fatih Gundogdu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ferit Soylu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Levent Erkan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Orkan Tatli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sadiye Mavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ali Yavuzcan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ali Yavuzcan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gundogdu, F., Soylu, F., Erkan, L. et al. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors). Arch Gynecol Obstet 283, 1397–1402 (2011). https://doi.org/10.1007/s00404-010-1589-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-010-1589-8

Keywords

Search

Navigation